Haopeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Haopeng Wang has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
- Chenqi Xu
State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
13 shared publications Shizhen Qiu
11 shared publicationsKun Wang
8 shared publicationsLi Li
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
7 shared publicationsYuwei Huang
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Lingang Laboratory, Shanghai 201203, China
7 shared publicationsHua Li
Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
6 shared publications
Latest Publications
- 10 November 2026
- Published by Springer Nature in Gene Therapy
Perspectives on cell and gene therapy: insights from the 5th China Annual Congress on CGT
Cell and gene therapy (CGT) represents a paradigm shift in medicine, offering immense potential to correct inherited genetic defects and provide healthy or empowered cells for therapy, thereby revolutionizing the treatment of cancers, chronic diseases, and hereditary diseases. Against a backdrop of rapid technological advancements and accelerating commercialization in the field, the 5th China Annual Congress on Cell and Gene Therapy was held in Haikou, Hainan, from November 20 to 22, 2025. At the congress, 175 speakers from around the world gave presentations on immune cell therapeutics, gene therapy, stem cell-based regenerative medicine, and regulatory frameworks alongside industrialization. These presentations highlighted that immune cell therapies are expanding beyond hematologic malignancies into solid tumors and autoimmune diseases. Concurrently, gene therapy has demonstrated promising clinical efficacy in treating genetic disorders alongside the evolution of therapeutic tools, while stem cell-based regenerative medicine has advanced both in fundamental research and in clinical translation for tissue repair. The congress also addressed the current status and challenges of China's regulatory system and industrialization landscape. Although the preliminary clinical outcomes of most reported CGT therapies are encouraging, long-term efficacy and safety require further observation. Furthermore, critical challenges remain, including the absence of harmonized potency assays and interoperable real-world evidence systems, manufacturing scalability and cost barriers, and the need for further refinement of the regulatory framework to accommodate rapid technological evolution. This report summarizes the key advancements and outstanding issues discussed at the congress, aiming to facilitate the sustainable and robust development of the CGT field.
- 10 November 2026
- Published by Springer Nature in Gene Therapy
Perspectives on cell and gene therapy: insights from the 5th China Annual Congress on CGT
Cell and gene therapy (CGT) represents a paradigm shift in medicine, offering immense potential to correct inherited genetic defects and provide healthy or empowered cells for therapy, thereby revolutionizing the treatment of cancers, chronic diseases, and hereditary diseases. Against a backdrop of rapid technological advancements and accelerating commercialization in the field, the 5th China Annual Congress on Cell and Gene Therapy was held in Haikou, Hainan, from November 20 to 22, 2025. At the congress, 175 speakers from around the world gave presentations on immune cell therapeutics, gene therapy, stem cell-based regenerative medicine, and regulatory frameworks alongside industrialization. These presentations highlighted that immune cell therapies are expanding beyond hematologic malignancies into solid tumors and autoimmune diseases. Concurrently, gene therapy has demonstrated promising clinical efficacy in treating genetic disorders alongside the evolution of therapeutic tools, while stem cell-based regenerative medicine has advanced both in fundamental research and in clinical translation for tissue repair. The congress also addressed the current status and challenges of China's regulatory system and industrialization landscape. Although the preliminary clinical outcomes of most reported CGT therapies are encouraging, long-term efficacy and safety require further observation. Furthermore, critical challenges remain, including the absence of harmonized potency assays and interoperable real-world evidence systems, manufacturing scalability and cost barriers, and the need for further refinement of the regulatory framework to accommodate rapid technological evolution. This report summarizes the key advancements and outstanding issues discussed at the congress, aiming to facilitate the sustainable and robust development of the CGT field.
- Open Access
- 15 October 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
PD-L1 transmembrane domain substitution overcomes CAR-T exhaustion driven by tonic signaling
- 15 October 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
Open AccessPD-L1 transmembrane domain substitution overcomes CAR-T exhaustion driven by tonic signaling
- 9 October 2026
- Published by Springer Nature in Nature Reviews Immunology
- p. 1-15
LAG3 checkpoint function and its mechanism of action in therapeutic targeting
- 9 October 2026
- Published by Springer Nature in Nature Reviews Immunology
- p. 1-15
LAG3 checkpoint function and its mechanism of action in therapeutic targeting
- 14 September 2026
- Published by Springer Nature in Cell Research
- Vol. 36 (10) , 830-832
Author Correction: Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness
- 14 September 2026
- Published by Springer Nature in Cell Research
- Vol. 36 (10) , 830-832
Author Correction: Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness
- 10 July 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (8) , 1354-1362.e4
FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function
- 10 July 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (8) , 1354-1362.e4
FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function
- 30 April 2026
- Published by Elsevier in Cancer Cell
- Vol. 44 (5) , 902-904
T cell extracellular vesicles go nuclear to turn cold tumors hot
- 30 April 2026
- Published by Elsevier in Cancer Cell
- Vol. 44 (5) , 902-904
T cell extracellular vesicles go nuclear to turn cold tumors hot
- Open Access
- 16 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e19746
Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma
Major challenges of developing CAR‑T cell therapy for head and neck squamous cell carcinoma (HNSCC) include identifying a robust tumor antigen and a suitable CAR design. Here, we validate chondroitin sulfate proteoglycan 4 (CSPG4) as a highly expressed, prognostic antigen in HPV‑negative HNSCC that drives tumor proliferation. By grafting the murine single‐chain variable fragment (scFv) 763.74 complementarity determining regions (CDRs) onto a human antibody framework engineered to minimize surface positive‑charge patches and immunogenic epitopes, we generated humanized CSPG4 (CSPG4 Hu ) CAR‑T cells with reduced tonic signaling and alleviated exhaustion. Transcriptomic and metabolic profiling reveal that this biophysical refinement reprograms CAR‐T cells away from a glycolytic, terminal exhaustion state toward a PI3K/Akt‐driven stem‐like state. Consequently, CSPG4 Hu CAR‐T cells demonstrate superior persistence and potent antitumor efficacy across systemic xenograft and patient‐derived xenograft models. Our study establishes a rational engineering framework that links biophysical CAR design to transcriptomic and metabolic rejuvenation, offering a promising therapeutic candidate for advanced HNSCC.
- 16 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e19746
Open AccessHumanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma
Major challenges of developing CAR‑T cell therapy for head and neck squamous cell carcinoma (HNSCC) include identifying a robust tumor antigen and a suitable CAR design. Here, we validate chondroitin sulfate proteoglycan 4 (CSPG4) as a highly expressed, prognostic antigen in HPV‑negative HNSCC that drives tumor proliferation. By grafting the murine single‐chain variable fragment (scFv) 763.74 complementarity determining regions (CDRs) onto a human antibody framework engineered to minimize surface positive‑charge patches and immunogenic epitopes, we generated humanized CSPG4 (CSPG4 Hu ) CAR‑T cells with reduced tonic signaling and alleviated exhaustion. Transcriptomic and metabolic profiling reveal that this biophysical refinement reprograms CAR‐T cells away from a glycolytic, terminal exhaustion state toward a PI3K/Akt‐driven stem‐like state. Consequently, CSPG4 Hu CAR‐T cells demonstrate superior persistence and potent antitumor efficacy across systemic xenograft and patient‐derived xenograft models. Our study establishes a rational engineering framework that links biophysical CAR design to transcriptomic and metabolic rejuvenation, offering a promising therapeutic candidate for advanced HNSCC.
- Open Access
- 9 February 2026
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 18
Genetically-determined systemic lupus erythematosus requires persistent CAR-T therapy: challenging the transient depletion paradigm
Baichuan Liu, Wenchen Ruan, Jingwei Jiang, Jinjiao Wang, Li Li, Xindong Liu, Haopeng Wang; Genetically-determined systemic lupus erythematosus requires per
- 9 February 2026
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 18
Open AccessGenetically-determined systemic lupus erythematosus requires persistent CAR-T therapy: challenging the transient depletion paradigm
Baichuan Liu, Wenchen Ruan, Jingwei Jiang, Jinjiao Wang, Li Li, Xindong Liu, Haopeng Wang; Genetically-determined systemic lupus erythematosus requires per
- Open Access
- 29 January 2026
- Published by Springer Nature in Research Square
Targeting pulmonary fibrosis with DDR2-specific chimeric antigen receptor macrophages
Idiopathic pulmonary fibrosis (IPF) is a fatal disease with a critical unmet need in therapeutic options. Chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein (FAP) have shown potential for IPF, but other cell-based approaches remain under-explored. In this study, we generated CAR macrophages (DDR2-CARM) targeting DDR2, a collagen receptor specifically upregulated in activated stromal cells, for the treatment of IPF. Murine DDR2-CARM exerted DDR2-specific phagocytosis, upregulation of antifibrotic cytokines, chemokines and matrix metalloproteinases in vitro; and mitigated pulmonary fibrosis in bleomycin-induced unilateral pulmonary fibrosis (UPF) mouse models by targeting DDR2 + stromal cells and degrading collagen. Single-cell RNA sequencing revealed that DDR2-CARM treatment led to attenuation of chronic inflammation accompanied by reduced infiltration of profibrotic neutrophils in the fibrotic lungs. Additionally, human DDR2-CARM suppressed fibrosis in precision-cut lung slices (PCLS) from IPF patients. Thus, DDR2 emerges as a new antifibrotic target, and DDR2-CARM represent potent remodelers of both stromal and immune activities in fibrotic tissues, holding therapeutic potential for IPF.
- 29 January 2026
- Published by Springer Nature in Research Square
Open AccessTargeting pulmonary fibrosis with DDR2-specific chimeric antigen receptor macrophages
Idiopathic pulmonary fibrosis (IPF) is a fatal disease with a critical unmet need in therapeutic options. Chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein (FAP) have shown potential for IPF, but other cell-based approaches remain under-explored. In this study, we generated CAR macrophages (DDR2-CARM) targeting DDR2, a collagen receptor specifically upregulated in activated stromal cells, for the treatment of IPF. Murine DDR2-CARM exerted DDR2-specific phagocytosis, upregulation of antifibrotic cytokines, chemokines and matrix metalloproteinases in vitro; and mitigated pulmonary fibrosis in bleomycin-induced unilateral pulmonary fibrosis (UPF) mouse models by targeting DDR2 + stromal cells and degrading collagen. Single-cell RNA sequencing revealed that DDR2-CARM treatment led to attenuation of chronic inflammation accompanied by reduced infiltration of profibrotic neutrophils in the fibrotic lungs. Additionally, human DDR2-CARM suppressed fibrosis in precision-cut lung slices (PCLS) from IPF patients. Thus, DDR2 emerges as a new antifibrotic target, and DDR2-CARM represent potent remodelers of both stromal and immune activities in fibrotic tissues, holding therapeutic potential for IPF.